Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ORTX Orchard Therapeutics > Main Composition
ORTX Orchard Therapeutics
0.437
-0.005-1.13%
All
YOY
Do not show
Business Unit:USD
nameYOYOperating income%
Collaboration revenue--975K58.21%
Product revenue, net--700K41.79%
Region Unit:USD
nameYOYOperating income%
United Kingdom--1.68M100.00%
Company Overview More
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
CEO: Dr. Hubert Gaspar
Market: NASDAQ
Listing Date: 10/31/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist